SEARCH

SEARCH BY CITATION

References

  • 1
    Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet 1997;349:13071310.
  • 2
    Arteaga E, Araujo AQ, Buck P, et al. Plasma amino-terminal pro–B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 2005;150:12281232.
  • 3
    Biondo AW, Ehrhart EJ, Sisson DD, et al. Immunohistochemistry of atrial and brain natriuretic peptides in control cats and cats with hypertrophic cardiomyopathy. Vet Pathol 2003;40:501506.
  • 4
    Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509516.
  • 5
    Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:13281333.
  • 6
    Jefferies JL, Denfield SW, Price JF, et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr Cardiol 2006;27:402407.
  • 7
    McGrath MF, De Bold ML, De Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005;16:469477.
  • 8
    Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195203.
  • 9
    Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: Importance for assessing cardiac function in clinical practice. Clin Sci (London) 1999;97:689695.
  • 10
    Sisson DD. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim Pract 2004;34:11051126.
  • 11
    Moro C, Berlan M. Cardiovascular and metabolic effects of natriuretic peptides. Fundam Clin Pharmacol 2006;20:4149.
  • 12
    Poutanen T, Tikanoja T, Jaaskelainen P, et al. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes. Am Heart J 2006;151:725 e721725 e729.
  • 13
    Buchanan J. Prevalence of cardiovascular disorders. In: FoxP, SissonD, MoiseN, eds. Textbook of Canine and Feline Cardiology, 2nd ed. Philadelphia, PA: WB Saunders; 1999:457470.
  • 14
    Fox P. Feline cardiomyopathies. In: FoxP, SissonD, MoiseN, eds. Textbook of Canine and Feline Cardiology, 2nd ed. Philadelphia, PA: WB Saunders; 1999:621678.
  • 15
    MacLean HN, Abbott JA, Ward DL, et al. N-terminal atrial natriuretic peptide immunoreactivity in plasma of cats with hypertrophic cardiomyopathy. J Vet Intern Med 2006;20:284289.
  • 16
    Vollmar AM, Reusch C, Kraft W, et al. Atrial natriuretic peptide concentration in dogs with congestive heart failure, chronic renal failure, and hyperadrenocorticism. Am J Vet Res 1991;52:18311834.
  • 17
    Haggstrom J, Hansson K, Karlberg BE, et al. Plasma concentration of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels. Am J Vet Res 1994;55:698703.
  • 18
    Yoshimura M, Yasue H, Ogawa H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol 2001;79:730735.
  • 19
    Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464469.
  • 20
    Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170179.
  • 21
    MacDonald KA, Kittleson MD, Munro C, et al. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med 2003;17:172177.
  • 22
    Haggstrom J, Hansson K, Kvart C, et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin–angiotensin–aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997;58:7782.
  • 23
    Raine AE, Erne P, Burgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986;315:533537.
  • 24
    Parsonage WA, Galbraith AJ, Koerbin GL, et al. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2005;95:883885.
  • 25
    Asano K, Masuda K, Okumura M, et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999;61:523529.
  • 26
    Schober KE, Fuentes VL, Bonagura JD. Comparison between invasive hemodynamic measurements and noninvasive assessment of left ventricular diastolic function by use of Doppler echocardiography in healthy anesthetized cats. Am J Vet Res 2003;64:93103.
  • 27
    Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000;102:17881794.
  • 28
    Kim YJ, Sohn DW. Mitral annulus velocity in the estimation of left ventricular filling pressure: Prospective study in 200 patients. J Am Soc Echocardiogr 2000;13:980985.
  • 29
    Oyama MA, Sisson DD, Bulmer BJ, et al. Echocardiographic estimation of mean left atrial pressure in a canine model of acute mitral valve insufficiency. J Vet Intern Med 2004;18:667672.
  • 30
    Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30:15271533.
  • 31
    Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99:254261.
  • 32
    Koffas H, Dukes-McEwan J, Corcoran BM, et al. Pulsed tissue Doppler imaging in normal cats and cats with hypertrophic cardiomyopathy. J Vet Intern Med 2006;20:6577.
  • 33
    Carlos Sampedrano C, Chetboul V, Gouni V, et al. Systolic and diastolic myocardial dysfunction in cats with hypertrophic cardiomyopathy or systemic hypertension. J Vet Intern Med 2006;20:11061115.
  • 34
    Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993;7:247252.
  • 35
    Hansson K, Haggstrom J, Kvart C, et al. Left atrial to aortic root indices using two dimensional and M-mode echocardiography in Cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568575.
  • 36
    Kienle RD Echocardiography. In: KittlesonMD, KienleRD, eds. Small Animal Cardiovascular Medicine. St Louis, MO: Mosby Inc; 1998:95117.
  • 37
    Fox PR. Hypertrophic cardiomyopathy. Clinical and pathologic correlates. J Vet Cardiol 2003;5:3944.
  • 38
    Fox PR. Endomyocardial fibrosis and restrictive cardiomyopathy: Pathologic and clinical features. J Vet Cardiol 2004;6:2531.
  • 39
    Syme HM, Markwell PJ, Pfeiffer D, et al. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. J Vet Intern Med 2006;20:528535.
  • 40
    Syme HM, Barber PJ, Markwell PJ, et al. Prevalence of systolic hypertension in cats with chronic renal failure. J Am Vet Med Assoc 2002;220:17991804.
  • 41
    Connolly DJ, Cannata J, Boswood A, et al. Cardiac troponin I in cats with hypertrophic cardiomyopathy. J Feline Med Surg 2003;5:209216.
  • 42
    Herndon WE, Kittleson MD, Sanderson K, et al. Cardiac troponin I in feline hypertrophic cardiomyopathy. J Vet Intern Med 2002;16:558564.
  • 43
    Chetboul V, Tessier-Vetzel D, Escriou C, et al. Diagnostic potential of natriuretic peptides in the occult phase of Golden retriever muscular dystrophy cardiomyopathy. J Vet Intern Med 2004;18:845850.
  • 44
    Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnoea in patients with kidney disease: Insights from a randomized comparison. Kidney Int 2005;67:278284.
  • 45
    Mark PB, Stewart GA, Gansevoort RT, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant 2006;21:402410.
  • 46
    Meuller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942944.